Sana Biotechnology’s hypoimmune platform enables it to make a series of genetic modifications to cells, rendering the cells ...

First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and ...

Sana Biotechnology said a type 1 diabetes (T1D) patient received an allogeneic primary islet cell transplantation without ...

Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 ...

an allogeneic primary islet cell therapy engineered with Sana’s hypoimmune (HIP) technology, into a patient with type 1 diabetes without the use of any immunosuppression. The study was conducted ...

Researchers from Tokyo Metropolitan University have uncovered a significant link between age-related diabetes and the loss of ...

Sonja Schrepfer and the team at Sana. The clinical data are highly promising for patients and provide the first evidence in humans for overcoming allogeneic and autoimmune rejection with pancreatic ...

The following is a summary of “Identification of a pancreatic stellate cell gene signature and lncRNA interactions associated ...

Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...